Renal Toxicities of Newer Cancer Therapies: A Clinicopathological Approach
October 23, 2020 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Clinical Practice Session
Renal Toxicities of Newer Cancer Therapies: A Clinicopathological Approach
October 23, 2020 | 10:00 AM - 12:00 PM
Location: On-Demand
Session Description
The field of onconephrology is rapidly expanding. With this comes increasing incidence of renal toxicity due to anticancer medications. This session describes recent advances in this rapidly changing field, including learning risk factors, clinical presentation, and management of AKI that occurs after immunotherapy and other oncologic therapies.
Learning Objective(s)
- Identify risk factors, characteristics, and challenges in the diagnosis and management of AKI in onconephrology
- Describe the features of immune checkpoint inhibitor-induced AKI
- Discuss the risks and characteristics of chimeric antigen receptor T cell (CAR-T)-associated AKI
- Examine the thrombotic microangiopathies in onconephrology
Learning Pathway(s)
- Acute Kidney Injury
- Pathology
Moderators
- Abhijat Kitchlu, MD, MS
- Megan L. Troxell, MD, PhD
Presentations
- Risk Factors, Diagnosis, and Management of Immune Checkpoint Inhibitor-Associated AKI
10:00 AM - 10:30 AM
Meghan E. Sise, MD, MS
Meghan E. Sise, MD, MS
Dr. Meghan Sise is an assistant professor of medicine at Harvard Medical School and the Director of Onconephrology at Massachusetts General Hospital. She conducts patient-oriented research on patients with chronic viral infections and cancer.
Risk Factors, Diagnosis, and Management of Immune Checkpoint Inhibitor-Associated AKI
October 23, 2020 | 10:00 AM - 10:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Renal Lesions Associated with Immune Checkpoint Inhibitors: A Pathologic Analysis
10:30 AM - 11:00 AM
Leal C. Herlitz, MD
Leal C. Herlitz, MD
Leal Herlitz M.D. is the Director of Medical Kidney Pathology at the Cleveland Clinic in Cleveland, Ohio. She received her medical degree from Columbia University College of Physicians and Surgeons in New York, NY. She completed her residency training in Anatomic and Clinical pathology at Columbia University Medical Center, followed by a fellowship there in renal pathology. She remained at Columbia as faculty for 5 years, attaining the rank of associate professor, prior to joining the Cleveland Clinic in the summer of 2014. She is board certified in both anatomic and clinical pathology. She also engages in collaborative basic science and clinical research and is an author on over 50 peer-reviewed publications and book chapters.
Renal Lesions Associated with Immune Checkpoint Inhibitors: A Pathologic Analysis
October 23, 2020 | 10:30 AM - 11:00 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- AKI After Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor T Cell (CAR-T) Therapies
11:00 AM - 11:30 AM
Jonathan Hogan, MD
AKI After Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor T Cell (CAR-T) Therapies
October 23, 2020 | 11:00 AM - 11:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
- Drug-Induced Thrombotic Microangiopathy
11:30 AM - 12:00 PM
Kammi J. Henriksen, MD
Drug-Induced Thrombotic Microangiopathy
October 23, 2020 | 11:30 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
